```html

Ivermectin Toxicity: A Complete Patient‑Focused Guide

Overview

Ivermectin toxicity occurs when an individual ingests a dose of ivermectin that exceeds the therapeutic range, leading to systemic adverse effects. Ivermectin is an antiparasitic drug commonly prescribed for conditions such as onchocerciasis (river blindness), strongyloidiasis, scabies, and certain ectoparasitic infections. It is also used in veterinary medicine for livestock, horses, and companion animals.

Most cases of toxicity involve accidental overdose, intentional misuse, or the use of veterinary formulations meant for animals, which contain concentrations up to 10‑fold higher than human doses. While ivermectin is generally safe at prescribed doses (<200 µg/kg), serious toxicity is reported when doses exceed 400 µg/kg, especially in children, the elderly, or individuals with liver disease.

Who it affects: Healthy adults, children, pregnant women, and patients with liver impairment can all develop toxicity, but certain groups are at higher risk (see Risk Factors below). Worldwide, a 2022 analysis of poisoning databases from the United States, United Kingdom, and Australia identified roughly 1,200 reported ivermectin overdoses, with 12 % resulting in hospitalization and 1 % in death.<sup>[1] CDC, 2022</sup>

Symptoms

Symptoms typically appear within 2‑12 hours after ingestion, though severe neurotoxicity may be delayed up to 24‑48 hours. The clinical picture is broad because ivermectin primarily affects the central nervous system (CNS) and the gastrointestinal (GI) tract.

Neurologic

• Dizziness or light‑headedness: Often the first sign of excess drug.
• Headache: Ranges from mild throbbing to severe migraine‑like pain.
• Ataxia: Loss of coordination, difficulty walking, or clumsiness.
• Confusion or agitation: Disorientation, irritability, or even delirium.
• Seizures: Generalized tonic‑clonic seizures reported in doses >500 µg/kg.
• Coma: Rare, but possible with massive overdose or in patients with compromised blood‑brain barrier.
• Visual disturbances: Blurred vision, “floaters,” or temporary loss of visual acuity.

Gastrointestinal

• Nausea and vomiting (often the most immediate complaint).
• Abdominal cramping.
• Diarrhea, sometimes with blood if severe mucosal irritation occurs.

Dermatologic

• Rash or urticaria.
• Pruritus (itching) – can be secondary to histamine release.

Other Systemic

• Fever – usually low‑grade, associated with inflammatory response.
• Hypotension or tachycardia – may signal systemic toxicity.
• Muscle weakness or myalgia.

Causes and Risk Factors

Primary Causes

• Accidental overdose: Taking more tablets than prescribed or misreading dosing instructions (e.g., “1 tablet = 1 mg” vs “1 tablet = 10 mg”).
• Use of veterinary formulations: These products can contain 5–10 % ivermectin, far exceeding human therapeutic concentrations.
• Intentional misuse: Some individuals self‑medicate for unapproved indications (e.g., COVID‑19), often acquiring the drug online without medical supervision.
• Drug interactions: Concomitant use of CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can raise plasma levels.

Risk Factors

• Children < 12 years old (dose calculations are weight‑based).
• Elderly patients (> 65 years) with reduced hepatic clearance.
• Pre‑existing liver disease (cirrhosis, hepatitis) – reduces metabolism.
• Concurrent medications that inhibit P‑glycoprotein or CYP3A4.
• Pregnancy or lactation – placental transfer and drug excretion in breast milk are not fully understood.
• Genetic polymorphisms affecting drug‑metabolizing enzymes.

Diagnosis

Diagnosis is primarily clinical, supported by a thorough history and targeted investigations.

Key Diagnostic Steps

1. History taking: Inquire about the dose, formulation (human vs veterinary), time of ingestion, and any co‑taken substances.
2. Physical examination: Focus on neurologic assessment (cranial nerves, gait, reflexes), vital signs, and abdominal exam.
3. Laboratory tests:
   • Serum ivermectin concentration – not routinely available, but can be measured in specialized labs.
   • Complete blood count (CBC) and metabolic panel to assess organ function.
   • Liver function tests (AST, ALT, bilirubin) – elevated values suggest impaired clearance.
4. Imaging (if indicated): Head CT or MRI for severe neurologic symptoms to rule out intracranial hemorrhage or other pathology.
5. Electroencephalogram (EEG): May be performed in patients with seizures or altered mental status.

Treatment Options

There is no specific antidote for ivermectin toxicity; management is supportive and aimed at preventing complications.

Acute Care (Emergency Department)

• Gastric decontamination: If presentation is within 1‑2 hours of ingestion, a single dose of activated charcoal (1 g/kg, max 50 g) can reduce absorption.
• Supportive monitoring: Continuous cardiac and pulse‑oximetry monitoring; frequent neurologic checks.
• Seizure control: Benzodiazepines (e.g., lorazepam 0.1 mg/kg IV) are first‑line; refractory seizures may require loading with phenobarbital.
• Airway protection: Intubation for patients with decreasing consciousness or impending respiratory failure.
• Fluid resuscitation: Crystalloid IV fluids for hypotension; avoid hypotonic solutions.
• IV lipid emulsion therapy (ILE): Case reports suggest ILE (20 % Intralipid, 1.5 mL/kg bolus) may sequester lipophilic ivermectin, but evidence is limited; consider in severe, refractory cases.

Hospital Admission

• Observation for at least 24 hours for delayed neurotoxicity.
• Serial neurologic exams every 4‑6 hours.
• Laboratory monitoring of liver enzymes and renal function.

Long‑Term Management

• Consultation with a toxicologist or clinical pharmacologist.
• Neuro‑rehabilitation for patients with persistent ataxia or cognitive deficits.
• Psychiatric evaluation if overdose was intentional.

Living with Ivermectin Toxicity

Even after acute symptoms resolve, some patients may experience lingering effects. Below are practical tips for daily life.

• Medication reconciliation: Keep an up‑to‑date list of all drugs, supplements, and over‑the‑counter products to avoid future interactions.
• Gradual return to activities: Resume driving, operating machinery, or heavy lifting only after a clinician confirms normal neurologic function.
• Hydration and nutrition: Adequate fluid intake supports hepatic clearance; a balanced diet rich in antioxidants (berries, leafy greens) may aid liver recovery.
• Fall prevention: Use assistive devices (canes, grab bars) if gait remains unsteady.
• Follow‑up appointments: Schedule liver function tests 1‑2 weeks post‑discharge and a neurologic review at 1 month.
• Mental health support: Access counseling or support groups if the overdose was linked to anxiety, depression, or misinformation.

Prevention

Preventing ivermectin toxicity centers on education, safe prescribing, and proper storage.

• Prescriber vigilance: Verify patient weight before dosing; use pediatric dosing calculators.
• Clear labeling: Ensure patients receive written instructions that differentiate human tablets from veterinary products.
• Patient education: Discuss the risks of self‑medicating, especially using internet‑sourced products.
• Secure storage: Keep medication out of reach of children and locked away from pets.
• Pharmacy checks: Pharmacists should flag unusually high doses or veterinary formulations when patients request ivermectin.
• Public health messaging: Disseminate accurate information through reputable sources (CDC, WHO) to combat misinformation.

Complications

If not recognized or treated promptly, ivermectin toxicity can lead to serious, sometimes irreversible, complications:

• Permanent neurologic deficits: Chronic ataxia, peripheral neuropathy, or memory impairment.
• Acute respiratory distress syndrome (ARDS): Secondary to severe CNS depression and aspiration.
• Hepatic injury: Elevated transaminases may progress to acute liver failure in vulnerable patients.
• Seizure‑related injuries: Falls, head trauma, or fractures.
• Psychiatric sequelae: Post‑traumatic stress, anxiety, or depression after a severe overdose.

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. “Poisoning Surveillance System: Ivermectin.” 2022. https://www.cdc.gov.
2. Mayo Clinic. “Ivermectin: Uses, Side Effects, and Dosage.” Updated 2023. https://www.mayoclinic.org.
3. World Health Organization. “Ivermectin – Quality Assurance and Safety.” 2021. https://www.who.int.
4. Cleveland Clinic. “Drug Overdose and Toxicology.” 2022. https://my.clevelandclinic.org.
5. National Institutes of Health, Toxicology Data Network. “Ivermectin Toxicity.” 2023. https://toxnet.nlm.nih.gov.

```